24/7 Market News Snapshot 04 June, 2025 – Sagimet Biosciences Inc. Series A Common Stock (NASDAQ:SGMT)

June 4, 2025

DENVER, Colo., 04 June, 2025 (www.247marketnews.com) – (NASDAQ:SGMT) are discussed in this article.
Sagimet Biosciences Inc. has recently captured the attention of investors and analysts alike, showcasing a remarkable rise in pre-market trading where its stock soared over 50%, climbing to $5.46 from the previous close of $3.63. This surge in interest is accompanied by impressive trading volume, reflecting heightened confidence in the company’s innovative developments within the biopharmaceutical space.

Central to this optimism is the successful completion of Sagimet’s Phase 3 clinical trial for denifanstat, an oral fatty acid synthase (FASN) inhibitor targeted at treating moderate to severe acne vulgaris. This pivotal trial, conducted with Ascletis Bioscience Co. Ltd., included 480 participants and yielded significant results, meeting all primary and secondary endpoints while demonstrating excellent tolerability. Notably, the trial reported substantial improvements in treatment success rates, highlighting a marked reduction in both total and inflammatory lesions over a 12-week period.

David Happel, Sagimet’s Chief Executive Officer, expressed excitement about the trial’s outcomes, stating, “The data support the rationale for our continued development of FASN inhibitors as a novel therapeutic approach for acne, an area that has seen limited innovation for decades.” This positive momentum is further amplified by the initiation of a Phase 1 clinical trial for TVB-3567, another candidate in Sagimet’s FASN inhibitor portfolio.

As the global market for acne treatments continues to expand, Sagimet’s focus on novel therapeutic strategies positions the company as a key player in dermatological innovation. With a robust pipeline and a commitment to addressing unmet needs within the acne treatment landscape, Sagimet Biosciences is poised to make significant contributions to skin health improvement worldwide. The current bullish trend in the stock market reflects the excitement surrounding these advancements, marking an important milestone in the company’s journey.

Related news for (SGMT)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.